Detection, Evaluation and Treatment of High Blood Pressure, Joint National
Committee on Prevention. The Sixth Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. Arch Intern Med.1997;157:2413-2446.
Joint National Committee on Detection, Evaluation, and Treatment of
High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation,
and Treatment of High Blood Pressure (JNC V). Arch Intern Med.1993;153:154-183.
Psaty BM, Smith NS, Siscovick DS.
et al. Health outcomes associated with antihypertensive therapies used as
first-line agents: a systematic review and meta-analysis. JAMA.1997;277:739-745.
Veterans Administration Cooperative Study Group on Antihypertensive
Agents. Effects of treatment on morbidity in hypertension: results in patients
with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA.1967;202:116-122.
Veterans Administration Cooperative Study Group on Antihypertensive
Agents II. Effects of treatment: results in patients with diastolic blood pressure
averaging 90 through 114 mm Hg. JAMA.1970;213:1143-1152.
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ.1985;291:97-104.
Hypertension Detection and Follow-up Program Cooperative Group. The effect of treatment on mild hypertension: results of the Hypertension
Detection and Follow-up Program. N Engl J Med.1982;307:976-980.
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program,
III: reduction in stroke incidence among persons with high blood pressure. JAMA.1982;247:633-638.
Brown MJ, Palmer CR, Castaigne A.
et al. Morbidity and mortality in patients randomized to double-blind treatment
with a long-acting calcium channel blocker or diuretic in the international
nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet.2000;356:366-372.
Hansson L, Hedner T, Lund-Johansen P.
et al. Randomised trial of effects of calcium antagonists compared with diuretics
and beta-blockers on cardiovascular morbidity and mortality in hypertension:
the Nordic Diltiazem (NORDIL) study. Lancet.2000;356:359-365.
Dahlof B, Devereux RB, Kjeldsen SE.
et al. Cardiovascular morbidity and mortality in the Losartan Intervention
For Endpoint reduction in hypertension study (LIFE): a randomised trial against
ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research
Group. Major cardiovascular events in hypertensive patients randomized to
doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). JAMA.2000;283:1967-1975.
Hansson L, Lindholm LH, Niskanen L.
et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomised trial. Lancet.1999;353:611-616.
Hansson L, Lindholm LH, Ekbom T.
et al. Randomised trial of old and new antihypertensive drugs in elderly patients:
cardiovascular mortality and morbidity the Swedish Trial in Old Patients with
Hypertension-2 study. Lancet.1999;354:1751-1756.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research
Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting
enzyme inhibitor or calcium-channel blocker vs diuretic: the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.2002;288:2981-2997.
Pahor M, Psaty BM, Alderman MH.
et al. Health outcomes associated with calcium antagonists compared with other
first-line antihypertensive therapies: a meta-analysis of randomised controlled
Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure
lowering drugs: results of prospectively designed overviews of randomised
MacMahon S, Neal B. Differences between blood-pressure lowering drugs. Lancet.2000;356:352-353.
Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med.2002;21:2313-2324.
MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality
from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis.1986;29(suppl 1):99-118.
Collins R, Peto R, MacMahon S.
et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term
reductions in blood pressure: overview of randomised drug trials in their
epidemiologic context. Lancet.1990;335:827-838.
Mulrow CD, Cornell JA, Herrera CR, Kadri A, Farnett L, Aguilar C. Hypertension in the elderly: implications and generalizability of randomized
Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and
decreased risk of coronary heart disease. Arch Intern Med.1993;153:578-581.
Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned
from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology,
Diagnosis and Management. 2nd ed. New York, NY: Raven Press; 1995:253-279.
Carter AB. Hypotensive therapy in stroke survivors. Lancet.1970;1:485-489.
Hegeland A. Treatment of mild hypertension: a five-year controlled drug trial:
the Oslo Study. Am J Med.1980;69:725-732.
Liu L, Wang JG, Gong L.
et al. Comparison of active treatment and placebo in older Chinese patients
with isolated systolic hypertension. J Hypertens.1998;16:1823-1829.
Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality
Miettinen TA, Huttunen JK, Naukkarinen V.
et al. Multifactorial primary prevention of cardiovascular diseases in middle-aged
men: risk factor changes, incidence and mortality. JAMA.1985;254:2097-2102.
Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chronic Dis.1966;19:227-240.
Sprackling ME, Mitchell JRA, Short AH, Watt G. Blood pressure reduction in the elderly: a randomised controlled trial
of methyldopa. BMJ.1981;283:1151-1153.
The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment
based on the beta-blocker oxprenolol: the International Prospective Primary
Prevention Study in Hypertension (IPPPSH). J Hypertens.1985;3:379-392.
SCOPE Trial Investigators. Primary results of SCOPE. Presented at: International Society of Hypertension; June 27, 2002;
Prague, Czech Republic.
Hansson L, Lithell H, Skoog I.
et al. Study on Cognition and Prognosis in the Elderly (SCOPE). Blood Press.1999;8:177-183.
Barraclough M, Joy MD, MacGregor GA.
et al. Control of moderately raised blood pressure: report of a co-operative
randomized controlled trial. BMJ.1973;3:434-436.
Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA.1974;229:409-418.
Smith WM. Treatment of mild hypertension: results of a ten-year intervention
trial. Circ Res.1977;40(5 suppl 1):I98-I105.
Perry Jr HM, Goldman AI, Lavin MA.
et al. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility
study. Ann N Y Acad Sci.1978;304:267-288.
Not Available. The Australian therapeutic trial in mild hypertension: report by the
Management Committee Lancet.1980;1:1261-1267.
Kuramoto K, Matsushita S, Kuwajima I, Murakami M. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J.1981;22:75-85.
Amery A, Birkenhager W, Brixko P.
et al. Mortality and morbidity from the European Working Party on High Blood
Pressure in the Elderly trial. Lancet.1985;1:1349-1354.
Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in
primary care. BMJ.1986;293:1145-1151.
Wilhelmsen L, Berglund G, Elmfeldt D.
et al. Beta-blockers versus diuretics in hypertensive men: main results from
the HAPPHY trial. J Hypertens.1987;5:561-572.
Perry Jr MH, Smith WM, McDonald RH.
et al. Morbidity and mortality in the Systolic Hypertension in the Elderly
Program (SHEP) pilot study. Stroke.1989;20:4-13.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons
with isolated systolic hypertension: final results of the Systolic Hypertension
in the Elderly Program (SHEP). JAMA.1991;265:3255-3264.
Kostis JB, Davis BR, Cutler J.
et al. Prevention of heart failure by antihypertensive drug treatment in older
persons with isolated systolic hypertension. JAMA.1997;278:212-216.
Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension
Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older
adults: principal results. BMJ.1992;304:405-412.
The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic
attack or nondisabling ischemic stroke. Stroke.1993;24:543-548.
PATS Collaborating Group. Post-Stroke Antihypertensive Treatment Study: a preliminary report. Chin Med J (Engl).1995;108:710-717.
Eriksson S, Olofsson BO, Wester PO.for the TEST study group. Atenolol in secondary prevention after stroke. Cerebrovasc Dis.1995;5:21-25.
Borhani NO, Mercuri M, Borhani PA.
et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis
Study (MIDAS): a randomized controlled trial. JAMA.1996;276:785-791.
Staessen JA, Fagard R, Thijs L.
et al. , for the Systolic Hypertension in Europe Trial Investigators. Randomised double-blind comparison of placebo and active treatment
for older patients with isolated systolic hypertension. Lancet.1997;350:757-764.
Staessen JA, Thijs L, Birkenhager WH, Bulpitt CJ, Fagard R. Update on the Systolic Hypertension in Europe (SYST-EUR) Trial. Hypertension.1999;33:1476-1477.
Rosei EA, Dal Palu C, Leonetti G.
et al. , for the VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclerosis
Study. J Hypertens.1997;15:1337-1344.
Estacio RO, Jeffers BW, Hiatt MR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular
outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med.1998;338:645-652.
Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes
and hypertension. N Engl J Med.2000;343:1969.
Tatti P, Pahor M, Byington RP.
et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular
Events Trial (FACET) in patients with hypertension and non-insulin dependent
diabetes mellitus. Diabetes Care.1998;21:597-603.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 38. BMJ.1998;317:703-713.
UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular
and microvascular complications in type 2 diabetes: UKPDS 39. BMJ.1998;317:713-720.
National Intervention Cooperative Study in Elderly Hypertensives Study
Group. Randomized double-blind comparison of a calcium antagonist and a diuretic
in elderly hypertensives. Hypertension.1999;34:1129-1133.
Agodoa LY, Appel L, Bakris GL.
et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive
Wright Jr JT, Bakris G, Green T.
et al. Effect of blood pressure lowering and antihypertensive drug class on
progression of hypertensive kidney disease: results from the AASK trial. JAMA.2002;288:2421-2431.
Wright J.for the AASK Study Group Investigators. The African-American Study of Kidney Disease and Hypertension. Presented at: American Society of Hypertension; May 18, 2002; New
PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure-lowering regimen
among 6105 individuals with previous stroke or transient ischaemic attack. Lancet.2001;358:1033-1041.
Parving HH, Lehnert H, Brochner-Mortensen J.
et al. , for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria
Study. The effect of irbesartan on the development of diabetic nephropathy
in patients with type 2 diabetes. N Engl J Med.2001;345:870-878.
Lewis EJ, Hunsicker LG, Clarke WR.
et al. Renoprotective effect of angiotensin-receptor antagonist irbesartan
in patients with nephropathy due to type 2 diabetes. N Engl J Med.2001;345:851-860.
The ANBP2 Investigators. Primary results of the Australian National Blood Pressure 2 Trial. Presented at: International Society of Hypertension; June 23-27,
2002; Prague, Czech Republic.
Wing LMH, Reid CM, Ryan P.
et al. for the Second Australian National Blood Pressure Study Group. A comparison of outomces with angiotensin-converting-enzyme inhibitors
and diuretics for hypertension in the elderly. N Engl J Med.2003;348:583-592.
Black HR, Grimm J RH, Hansson L.
et al. Controlled Onset Verapamil Investigation of Cardiovascular Endpoints:
CONVINCE primary results. Presented at: American Society of Hypertension; May 18, 2002; New
Zanchetti Z, Bond G, Hennig M.
et al. Calcium antagonist lacidipine slows down progression of asymptomatic
caroitd atherosclerosis: principal results of the European Lacidipine Study
on Atherosclerosis (ELSA): a randomized, double-blind, long-term trial. Circulation.2002;106:2422-2427.
Sewester CS, Dombek CE, Olin BR, Scott JA, Hebel SK, Novak KK, eds . Drug Facts and Comparisons. St Louis, Mo: Wolters Kluwer Co; 1996.
Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from
clinical trials. Stat Med.1989;8:141-151.
Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis
of randomized controlled trials. J Clin Epidemiol.1997;50:683-691.
Ekbom T, Dahlof B, Hansson L, Lindholm SH, Schersten B, Wester PO. Antihypertensive efficacy and side effects of three betα-blockers
and a diuretic in elderly hypertensives: a report from the STOP-Hypertension
study. J Hypertens.1992;10:1525-1530.
Alderman MH, Furberg CD, Kostis JB.
et al. Hypertension guidelines: criteria that might make them more clinically
useful. Am J Hypertens.2002;15:917-923.
Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease,
I: treatments following myocardial infarction. JAMA.1988;260:2088-2093.
Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis.1997;39:445-456.
Heidenreich PA, McDonald KM, Hastie T.
et al. Meta-analysis of trials comparing β-blockers, calcium antagonists,
and nitrates for stable angina. JAMA.1999;281:1927-1936.
Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure:
a meta-analysis of randomized clinical trials. J Am Coll Cardiol.1997;30:27-34.
Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure:
a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation.1998;98:1184-1191.
Task Force on the Management of Stable Angina Pectoris. Management of stable angina pectoris: recommendations of the Task Force
of the European Society of Cardiology. Eur Heart J.1997;18:394-413.
Gibbons RJ, Chatterjee K, Daley J.
et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic
stable angina: executive summary and recommendations. Circulation.1999;99:2829-2848.
Ryan TJ, Antman EM, Brooks NH.
et al. 1999 Update: ACC/AHA guidelines for the management of patients with
acute myocardial infarction: executive summary and recommendations. Circulation.1999;100:1016-1030.
Braunwald E, Antman EM, Beasley JW.
et al. ACC/AHA guidelines for the management of patients with unstable angina
and non–ST-segment elevation myocardial infarction: executive summary
and recommendations. Circulation.2000;102:1193-1209.
Williams SV, Fihn SD, Gibbons RJ. Guidelines for the management of patients with chronic stable angina:
diagnosis and risk stratification. Ann Intern Med.2001;135:530-547.
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on
cardiovascular events in high-risk patients. N Engl J Med.2000;342:145-153.
Flather MD, Yusuf S, Kober L.
et al. , for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular
dysfunction: a systematic overview of data from individual patients. Lancet.2000;355:1575-1581.
Garg R, Yusuf S.for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors
on mortality and morbidity in patients with heart failure. JAMA.1995;273:1450-1456.
Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs
in patients with type 2 diabetes. Diabetes Care.2000;23:888-892.
Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular
disease and death using pooled repeated biennial measurements: Framingham
Heart Study, 30-year follow-up. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham
Study: an Epidemiological Investigation of Cardiovascular Disease. Bethesda,
Md: National Institutes of Health; 1987. NIH No. 87-2703.
Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparisons for estimated efficacy of competing
interventions: empirical evidence from published meta-analyses. BMJ.2003;326:472.
Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials.1982;3:345-353.
Blackwelder WC, Chang MA. Sample size graphs for "proving the null hypothesis". Control Clin Trials.1984;5:97-105.
Neaton JD, Grimm Jr RH, Prineas RJ.
et al. , for the Treatment of Mild Hypertension Research Group. Treatment of Mild Hypertension Study (TOMHS): final results. JAMA.1993;270:713-724.